Latest Government Tenders From Italy

ItalyTenders provides latest updates on tenders from Italy. The information is collected from various sources like: Purchaser's websites, News papers and other Italy Government Tenders sites.Subscriber can view and download unlimited number of public tenders, published by various agencies of Italy Government.

Transposition VIII tranche Medicines 2022: CHLOREXIDINE GLUCONATE/ISOPROPYL ALCOHOL (2% w/v + 70% v/v)/ 26 ML

ITT Ref No.:  91673837

Deadline:  31 Dec 2025

View Details

Transposition VIII tranche Medicines 2022: CHLOREXIDINE GLUCONATE/ISOPROPYL ALCOHOL (2% w/v + 70% v/v)/10.5 ML

ITT Ref No.:  91673834

Deadline:  31 Dec 2025

View Details

Transposition VIII tranche of drugs 2022: BUPRENORPHINE HYDROCHLORIDE/NALOXONE HYDROCHLORIDE DIHYDRATE 4 MG/1 MG

ITT Ref No.:  91673831

Deadline:  31 Dec 2025

View Details

Transposition VIII tranche of drugs 2022: BUPRENORPHINE HYDROCHLORIDE/NALOXONE HYDROCHLORIDE DIHYDRATE 8 MG/2 MG

ITT Ref No.:  91673829

Deadline:  31 Dec 2025

View Details

Transposition VIII tranche of drugs 2022: BUPRENORPHINE HYDROCHLORIDE/NALOXONE HYDROCHLORIDE DIHYDRATE 2 MG/0.5 MG

ITT Ref No.:  91673827

Deadline:  31 Dec 2025

View Details

Transposition VIII tranche of drugs 2022: DULAGLUTIDE

ITT Ref No.:  91673822

Deadline:  31 Dec 2025

View Details

Transposition VIII tranche of drugs 2022: SACUBITRIL VALSARTAN SODIUM SALT COMPLEX 24 MG+26 MG

ITT Ref No.:  91673820

Deadline:  31 Dec 2025

View Details

Transposition VIII tranche of drugs 2022: SACUBITRIL VALSARTAN SODIUM SALT COMPLEX 97 MG+103 MG

ITT Ref No.:  91673817

Deadline:  31 Dec 2025

View Details

Transposition VIII tranche of drugs 2022: VILDAGLIPTIN

ITT Ref No.:  91673814

Deadline:  31 Dec 2025

View Details

Transposition VIII tranche of Medicines 2022: CHLOREXIDINE GLUCONATE/ISOPROPYL ALCOHOL (2% w/v + 70% v/v)/ 3ML

ITT Ref No.:  91673813

Deadline:  31 Dec 2025

View Details
  Chat with us

Home

Important Links

info@italytenders.com


Copyright © 2014-2025  ItalyTenders.com. All Rights Reserved.